Cargando…
Identification of the best cut-off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis
Autores principales: | Kostik, Mikhail M, Dubko, Margarita, Masalova, Vera, Snegireva, Ludmila, Chikova, Irina, Kornishina, Tatyana, Isupova, Eugenia, Likhacheva, Tatyana, Glebova, Natalia, Kuchinskaya, Ekaterina, Balbotkina, Eugenia, Buchinskaya, Natalia, Kalashnikova, Olga, Chasnyk, Vyacheslav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191251/ http://dx.doi.org/10.1186/1546-0096-12-S1-P213 |
Ejemplares similares
-
Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis
por: Kostik, Mikhail M, et al.
Publicado: (2015) -
PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases
por: Kostik, MM, et al.
Publicado: (2013) -
Anemia in children with JIA: is it really driven by hepcidin level, or by a set of factors of a chronic disease
por: Egorov, Andrey, et al.
Publicado: (2014) -
Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study
por: Kostik, Mikhail, et al.
Publicado: (2023) -
Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M., et al.
Publicado: (2022)